Retatrutide cost projections
LY-3437943 (investigational, Eli Lilly). Investigational — chronic weight management, T2D.
Retatrutide is investigational as of April 2026 — it's in Phase 3 and not FDA approved. No legitimate pricing exists yet. We've included this page as a placeholder and to flag the anti-patterns readers should avoid (research-peptide vendors selling 'retatrutide' for human use). Pricing projections once approved are our informed guesses based on tirzepatide and semaglutide benchmarks.
Realistic cost by scenario
| Scenario | Estimated / month |
|---|---|
| If Lilly prices at parity with Zepbound on launchReasonable base case given mechanism and efficacy | ~$1,059–$1,300 (projected) |
| If Lilly uses premium pricing for the efficacy leaderPossible given Phase 2 efficacy data | $1,400–$1,800 (projected) |
| Insurance coverage on launchNew drugs take 12-24 months for broad formulary adoption | Minimal in the first year |
| Buying from a 'research peptide' vendor labeled 'retatrutide'Unapproved, illegal for human use, subject to FDA enforcement | Don't. |
Frequently asked
When will retatrutide be FDA approved?
Eli Lilly has indicated expected approval timing in 2026-2027 contingent on Phase 3 TRIUMPH trial readouts. Exact timing depends on regulatory filing and FDA review.
Can I get retatrutide legally in the US right now?
No. It's investigational. The only legal access is through enrollment in a Lilly-sponsored clinical trial. Research-peptide vendors selling 'retatrutide' have been subjects of FDA warning letters (December 2024).
Will insurance cover retatrutide when approved?
Initial coverage will be limited. Even Zepbound and Wegovy, which have been approved for years, have inconsistent obesity coverage. New drugs typically take 12-24 months to reach broad formulary coverage, and obesity-specific coverage remains a patchwork by plan and employer.